Central European Vaccination Advisory Group (CEVAG) guidance statement on recommendations for the introduction of HPV vaccines
Language English Country Germany Media print-electronic
Document type Journal Article, Practice Guideline, Research Support, Non-U.S. Gov't
- MeSH
- Cost-Benefit Analysis MeSH
- Child MeSH
- Adult MeSH
- Papillomavirus Infections economics epidemiology virology MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Uterine Cervical Neoplasms economics epidemiology virology MeSH
- Advisory Committees * MeSH
- Vaccination * economics MeSH
- Papillomavirus Vaccines administration & dosage economics MeSH
- Check Tag
- Child MeSH
- Adult MeSH
- Humans MeSH
- Adolescent MeSH
- Young Adult MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Practice Guideline MeSH
- Geographicals
- Europe epidemiology MeSH
- Names of Substances
- Papillomavirus Vaccines MeSH
Vaccines against human papillomavirus (HPV), the primary causative agent in cervical cancer, are licensed. This paper contains the Central European Vaccination Advisory Group (CEVAG) guidance statement on the introduction of HPV vaccines in central Europe. Eight countries currently have medical representatives on CEVAG: the Czech Republic, Estonia, Hungary, Lithuania, Poland, Romania, Slovakia and Turkey. By raising awareness and disseminating information, CEVAG aims to promote the efficient and safe use of vaccines to prevent, control and if possible eliminate infectious diseases. In January 2008, the European Centre for Disease Prevention and Control published a report entitled Guidance for the Introduction of HPV Vaccines in EU Countries. Members of CEVAG have taken the information relevant to their countries from this report and, with consideration of local issues, produced these guidance recommendations for the introduction of HPV vaccines in the CEVAG region, which may be adapted for use in individual countries.
See more in PubMed
Am J Surg Pathol. 2006 Dec;30(12):1513-8 PubMed
Br J Cancer. 2002 Jul 1;87(1):61-4 PubMed
J Clin Pathol. 2002 Apr;55(4):244-65 PubMed
Emerg Infect Dis. 2007 Jan;13(1):28-41 PubMed
Lancet. 2007 Sep 8;370(9590):890-907 PubMed
J Clin Pathol. 2007 Sep;60(9):961-5 PubMed
Lancet. 2007 Jun 30;369(9580):2161-2170 PubMed
J Med Virol. 2000 May;61(1):65-9 PubMed
Vaccine. 2007 Jun 21;25(26):4931-9 PubMed
Int J Cancer. 2007 Aug 15;121(4):759-66 PubMed
Int J Cancer. 2007 Aug 1;121(3):621-32 PubMed
J Clin Virol. 2005 Mar;32 Suppl 1:S16-24 PubMed
Vaccine. 2007 Aug 14;25(33):6257-70 PubMed
Gynecol Oncol. 2007 Nov;107(2 Suppl 1):S2-5 PubMed
Int J Cancer. 1992 Nov 11;52(5):743-9 PubMed
Lancet. 2007 Jun 2;369(9576):1861-1868 PubMed
N Engl J Med. 2006 Jun 22;354(25):2645-54 PubMed
Ann Oncol. 2007 Oct;18(10):1708-15 PubMed
Lancet. 2004 Nov 13-19;364(9447):1757-65 PubMed
Asian Pac J Cancer Prev. 2007 Jul-Sep;8(3):339-47 PubMed
JAMA. 2003 Aug 13;290(6):781-9 PubMed
N Engl J Med. 2003 Feb 6;348(6):518-27 PubMed
Sex Transm Dis. 2002 Nov;29(11):725-35 PubMed
Br J Cancer. 2006 Dec 4;95(11):1459-66 PubMed
Lancet. 2006 Apr 15;367(9518):1247-55 PubMed
Int J Cancer. 2008 Jan 1;122(1):132-7 PubMed
Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):677-86 PubMed
J Med Virol. 1999 Aug;58(4):378-86 PubMed
Int J Gynecol Cancer. 2007 Nov-Dec;17(6):1307-13 PubMed
Emerg Infect Dis. 2003 Jan;9(1):37-48 PubMed
J Pathol. 1999 Sep;189(1):12-9 PubMed
